Related Experiment Video
Updated: Mar 16, 2026
11:10
Hyperinsulinemic-euglycemic Clamps in Conscious, Unrestrained Mice
Published on: November 16, 2011
96.1K
Glucagon-Like Peptide-1 (GLP-1) Receptor Agonists in Cardiac Disorders
Jamie Wroge1, Nancy Toedter Williams2
1Southwestern Oklahoma State University, Weatherford, OK, USA.
The Annals of Pharmacotherapy
|August 18, 2016
Summary
Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) show promise for treating cardiac disorders like myocardial infarction (MI), improving cardiac function and reducing MI size. However, their effectiveness in heart failure (HF) is less clear.
Area of Science:
- Cardiology
- Endocrinology
- Pharmacology
Background:
- Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) are primarily used for type 2 diabetes management.
- Emerging evidence suggests potential cardiovascular benefits of GLP-1 RAs.
- The role of GLP-1 RAs in specific cardiac conditions like myocardial infarction (MI) and heart failure (HF) requires comprehensive evaluation.
Purpose of the Study:
- To systematically review the existing literature on the efficacy of GLP-1 RAs in treating cardiac disorders.
- To specifically assess the impact of GLP-1 RAs on myocardial infarction (MI) and heart failure (HF).
Main Methods:
- Literature search conducted in MEDLINE and EMBASE databases up to May 2016.
- Included English-language, human clinical trials investigating GLP-1 RAs for cardiac disorders.
- Reviewed 18 trials involving patients with and without diabetes mellitus.
Main Results:
- Eleven trials on MI demonstrated significant benefits, including improved myocardial blood flow, left ventricular (LV) function, and reduced MI size.
- Seven trials on HF showed mixed results, with three trials indicating significant improvements in LV ejection fraction, cardiac index, and peak oxygen consumption.
- GLP-1 RAs exhibited potential pleiotropic cardioprotective effects beyond glycemic control.
Conclusions:
- GLP-1 RAs show potential efficacy in treating cardiac disorders, particularly myocardial infarction (MI), in patients with or without diabetes.
- These agents may offer cardioprotective benefits in cardiovascular disease.
- Evidence suggests GLP-1 RAs are more promising for MI treatment than for heart failure (HF).
Related Concept Videos
01:24Glucagon-like Receptor Agonists
1.2K
Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
1.2K
01:27Transducer Mechanism: Enzyme-Linked Receptors
4.7K
Enzyme-linked receptors are cell-surface receptors acting as an enzyme or associating with an enzyme intracellularly. They make excellent drug targets. Drugs can bind to the extracellular ligand-binding domain or directly affect their enzymatic domain and alter their activity.
Major types that are helpful drug targets include:
Major types that are helpful drug targets include:
4.7K
01:26Heart Failure Drugs: Inotropic Agents
1.8K
Positive inotropic agents are commonly used as the first line of treatment for heart failure. One such agent is digoxin, derived from the genus Digitalis, which has been known for centuries but effectively utilized since 1785. However, these cardiac glycosides can have potentially toxic effects due to their mechanism of action, which involves inhibiting Na+/K+-ATPase and increasing contractility. Digoxin is absorbed orally and distributed in various tissues, including the CNS. It has a long...
1.8K
01:06Oral Hypoglycemic Agents: Glinides
821
Repaglinide (Prandin) and Nateglinide (Starlix), known as glinides, are oral insulin secretagogues that stimulate insulin release from pancreatic β cells by closing the ATP-sensitive potassium channels (KATP channel). Repaglinide controls insulin release from pancreatic β cells by managing potassium efflux. It shares two binding sites with sulfonylureas and also has a unique site, indicating overlapping mechanisms of action. With a rapid onset and a 4-7 hour duration, it effectively...
821
01:23Dipeptidyl Peptidase 4 Inhibitors
876
Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...
876
01:15Hypoglycemia and Glucagon
1.2K
Without prolonged fasting, healthy individuals maintain blood glucose levels above 3.5 mM due to a well-adapted neuroendocrine counterregulatory system that effectively prevents acute hypoglycemia, a potentially life-threatening condition. The primary clinical scenarios for hypoglycemia encompass diabetes treatment, inappropriate production of endogenous insulin or insulin-like substances by tumors, and the use of glucose-lowering agents in non-diabetic individuals. Notably, hypoglycemia in the...
1.2K